VivoSeq
Oncology

Breast Neoplasms

38

Pipeline Programs↗

19

Active Trials↗

16

Companies Involved↗

Breast Neoplasms is a moderately active landscape with 38 programs across 16 companies. The most active players are Atossa Therapeutics, Inc., GSK, TerSera Therapeutics LLC. 28 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

32/100

Mech. Concentration

15/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Atossa Therapeutics, Inc.

1 program

Phase 2GSK logo

GSK

1 program

Phase 2T

TerSera Therapeutics LLC

1 program

Phase 2Merck & Co. logo

Merck & Co.

4 programs

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3BioNTech logo

BioNTech

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

29 of 35 classified programs — the dominant modality here.

17%ALL OTHERSAntibody–drug conjugate411%Monoclonal antibody26%

Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 88% of 40 pipeline programs.

Analysis

Trial Status

23

clinical trials

Recruiting13 · 57%
Completed4 · 17%
Active, not recruiting4 · 17%
Not yet recruiting2 · 9%

Clinical Trials

Trial Activity

23 trials

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06966700·2,400 enrolled
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06312176·1,200 enrolled
Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT05573893·800 enrolled
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT07060807·1,000 enrolled
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence to Evaluate Real-world Effectiveness, Safety Profile, Patient Compliance and Quality of Life
Recruiting·Novartis logoNovartis·N/A·NCT06830720·3,250 enrolled
A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07114601·421 enrolled
preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07287098·600 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07174336·920 enrolled
A Phase I, Open Label First in Human Study to Evaluate the Imaging Performance, Safety, Biodistribution and Pharmacokinetics of [68Ga]Ga-DWJ155 in Adult Patients With Advanced Breast Cancer and Advanced NSCLC
Recruiting·Novartis logoNovartis·Phase 1·NCT07117214·36 enrolled
Use of Imaging Markers by Fluorocholine PET/MR to Predict Molecular Subtypes and Clinical Outcomes of Breast Cancer: A Pilot Study
Recruiting·TTaipei Veterans General Hospital, Taiwan·N/A·NCT07587086·195 enrolled
Effect of Neoadjuvant Radiation and Prediction of Response to Treatment in Locally Advanced Breast Cancer
Recruiting·FFudan University·Phase 2·NCT05479409·70 enrolled
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease
Recruiting·BioNTech logoBioNTech·Phase 3·NCT07173751·558 enrolled
Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer (STAR-BREAST)
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07070128·800 enrolled
A Retrospective Study Comparing the Safety and Efficacy of Robotic-Assisted Versus Endoscopic-Assisted Axillary Lymph Node Dissection in Breast Cancer
Active, not recruiting·GGuangzhou Women and Children's Medical Center·N/A·NCT07693361·127 enrolled
A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer
Active, not recruiting·AAtossa Therapeutics, Inc.·Phase 2·NCT05607004·87 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)